Logan-Clubb L, Stacy M
Division of Neurology, University of Missouri-Columbia, School of Medicine, USA.
J Neurosci Nurs. 1995 Dec;27(6):344-7. doi: 10.1097/01376517-199512000-00005.
Interferon 1-beta (IFNB) (Betaseron) has been reported to reduce the frequency and severity of exacerbations in relapsing-remitting multiple sclerosis (MS). Adverse effects from this every other day injection are frequent, and most often include injection site reaction or flu-like symptoms. This open-labelled prospective study of MS patients receiving IFNB found that while injection site reactions and flu-like symptoms were seen in 90.0% and 76.7% of patients respectively, only two of 30 patients discontinued therapy for these problems.
据报道，干扰素1-β（IFNB）（倍泰龙）可降低复发缓解型多发性硬化症（MS）发作的频率和严重程度。这种隔日注射带来的不良反应很常见，最常出现的是注射部位反应或类流感症状。这项针对接受IFNB治疗的MS患者的开放性前瞻性研究发现，虽然分别有90.0%和76.7%的患者出现了注射部位反应和类流感症状，但30名患者中只有两人因这些问题而停止治疗。
